DEF: SCYNEXIS Proposes Reverse Stock Split to Maintain Nasdaq

SCYNEXIS, Inc. has scheduled a special meeting for May 19, 2026, to seek stockholder approval for a reverse stock split to regain compliance with Nasdaq minimum bid price requirements.

Summary

• The company is seeking approval for a reverse stock split at a ratio between 1-for-5 and 1-for-10.
• The board of directors will have the discretion to determine the final ratio and the timing of the implementation.
• The primary objective is to increase the per-share trading price to meet the Nasdaq Capital Market's $1.00 minimum bid price requirement.
• Failure to regain compliance by June 15, 2026, could result in delisting proceedings.
• The number of authorized shares will be reduced proportionately to the chosen split ratio.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a defensive, reactive measure necessitated by poor stock performance and the threat of delisting, which typically signals underlying financial distress.

Positives

• The reverse stock split is a proactive measure to avoid potential delisting from the Nasdaq Capital Market.
• A higher share price may improve marketability and potentially facilitate future capital raising efforts.
• The proposal includes a range of ratios, providing the board with flexibility to adapt to market conditions.

Negatives

• The need for a reverse stock split indicates a significant decline in the company's share price.
• Reverse stock splits are often viewed negatively by the market and may not result in a sustained increase in share price.
• The action may lead to the creation of odd lots, which can be more expensive for stockholders to trade due to higher relative brokerage commissions.

Risks

• There is no guarantee that the reverse stock split will result in a sustained increase in the share price.
• The company may still fail to meet Nasdaq's continued listing requirements even after the split.
• The split could be perceived negatively by investors, potentially leading to further downward pressure on the stock price.
• The reduction in the number of shares outstanding could adversely affect liquidity.

Future Outlook

The company intends to use the reverse stock split to maintain its Nasdaq listing and potentially improve its ability to raise capital in the future, though it acknowledges that success is not guaranteed.

Management Comments

• The Board believes that effecting the Reverse Stock Split is the most direct and reliable means available to the Company to regain compliance with the Bid Price Requirement.
• The Board believes that the increased market price of our common stock expected as a result of implementing a Reverse Stock Split could improve the marketability of our common stock.

Industry Context

StockSavvy.ai notes that reverse stock splits have become increasingly common among small-cap biotechnology firms struggling with depressed valuations and Nasdaq listing compliance, often serving as a last-resort mechanism to maintain institutional investor eligibility.

Comparison to Industry Standards

• The use of a reverse stock split to maintain Nasdaq listing is a standard, albeit often dilutive-in-perception, practice for companies in the biotech sector facing sub-$1.00 share prices.
• The proposed range of 1-for-5 to 1-for-10 is consistent with typical ratios used by similar-sized companies to achieve compliance.

Corporate Governance

Stakeholder Impact

• Shareholders will see a reduction in the number of shares held, though their percentage ownership remains unchanged.
• Potential for odd-lot holdings which may increase transaction costs for retail investors.
• Employees may benefit from a higher share price for equity-based compensation.

Next Steps

• Hold special meeting of stockholders on May 19, 2026.
• Board to determine final reverse stock split ratio if approved.
• File Certificate of Amendment with the Secretary of State of Delaware if the board proceeds.
• Publicly announce the final ratio and effective date.

Key Dates

Recommendation

The company is in a precarious position regarding its Nasdaq listing. While the reverse split is necessary for survival on the exchange, it does not address the underlying business performance issues that led to the share price decline. Investors should hold until there is evidence of operational improvement or successful capital raising.

Keywords

SCYNEXIS, SCYX, reverse stock split, Nasdaq compliance, proxy statement, biotech, corporate governance